| First Author | Lokken AA | Year | 2012 |
| Journal | Cancer Cell | Volume | 21 |
| Issue | 4 | Pages | 451-3 |
| PubMed ID | 22516254 | Mgi Jnum | J:189334 |
| Mgi Id | MGI:5445061 | Doi | 10.1016/j.ccr.2012.03.027 |
| Citation | Lokken AA, et al. (2012) Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell 21(4):451-3 |
| abstractText | KDM1A/LSD1, a histone H3K4/K9 demethylase and epigenetic regulator with roles in both gene activation and repression, has increased expression in multiple cancer types. Harris et al., in this issue of Cancer Cell, and Schenk et al. show that KDM1A may be a viable therapeutic target in treating AML. |
